BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 15840579)

  • 1. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease.
    Liu CW; Giasson BI; Lewis KA; Lee VM; Demartino GN; Thomas PJ
    J Biol Chem; 2005 Jun; 280(24):22670-8. PubMed ID: 15840579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.
    Maki RA; Holzer M; Motamedchaboki K; Malle E; Masliah E; Marsche G; Reynolds WF
    Free Radic Biol Med; 2019 Sep; 141():115-140. PubMed ID: 31175983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. alpha-Synuclein expression levels do not significantly affect proteasome function and expression in mice and stably transfected PC12 cell lines.
    Martìn-Clemente B; Alvarez-Castelao B; Mayo I; Sierra AB; Dìaz V; Milán M; Fariñas I; Gómez-Isla T; Ferrer I; Castaño JG
    J Biol Chem; 2004 Dec; 279(51):52984-90. PubMed ID: 15466467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-synuclein suppresses mitochondrial protease ClpP to trigger mitochondrial oxidative damage and neurotoxicity.
    Hu D; Sun X; Liao X; Zhang X; Zarabi S; Schimmer A; Hong Y; Ford C; Luo Y; Qi X
    Acta Neuropathol; 2019 Jun; 137(6):939-960. PubMed ID: 30877431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ER retention protein RER1 promotes alpha-synuclein degradation via the proteasome.
    Park HJ; Ryu D; Parmar M; Giasson BI; McFarland NR
    PLoS One; 2017; 12(9):e0184262. PubMed ID: 28877262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiological C-terminal truncation of α-synuclein potentiates the prion-like formation of pathological inclusions.
    Sorrentino ZA; Vijayaraghavan N; Gorion KM; Riffe CJ; Strang KH; Caldwell J; Giasson BI
    J Biol Chem; 2018 Dec; 293(49):18914-18932. PubMed ID: 30327435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons.
    McLean PJ; Kawamata H; Hyman BT
    Neuroscience; 2001; 104(3):901-12. PubMed ID: 11440819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations.
    Lewis KA; Yaeger A; DeMartino GN; Thomas PJ
    J Bioenerg Biomembr; 2010 Feb; 42(1):85-95. PubMed ID: 20148295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain.
    Kahle PJ; Neumann M; Ozmen L; Muller V; Jacobsen H; Schindzielorz A; Okochi M; Leimer U; van Der Putten H; Probst A; Kremmer E; Kretzschmar HA; Haass C
    J Neurosci; 2000 Sep; 20(17):6365-73. PubMed ID: 10964942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carboxy-terminal truncation and phosphorylation of α-synuclein elongates survival in a prion-like seeding mouse model of synucleinopathy.
    Sorrentino ZA; Hass E; Vijayaraghavan N; Gorion KM; Riffe CJ; Dhillon JS; Giasson BI
    Neurosci Lett; 2020 Jul; 732():135017. PubMed ID: 32371157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-Terminal Tyrosine Residue Modifications Modulate the Protective Phosphorylation of Serine 129 of α-Synuclein in a Yeast Model of Parkinson's Disease.
    Kleinknecht A; Popova B; Lázaro DF; Pinho R; Valerius O; Outeiro TF; Braus GH
    PLoS Genet; 2016 Jun; 12(6):e1006098. PubMed ID: 27341336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.
    Lee MK; Stirling W; Xu Y; Xu X; Qui D; Mandir AS; Dawson TM; Copeland NG; Jenkins NA; Price DL
    Proc Natl Acad Sci U S A; 2002 Jun; 99(13):8968-73. PubMed ID: 12084935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
    Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
    J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In parkinsonian substantia nigra, alpha-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity.
    Shamoto-Nagai M; Maruyama W; Hashizume Y; Yoshida M; Osawa T; Riederer P; Naoi M
    J Neural Transm (Vienna); 2007; 114(12):1559-67. PubMed ID: 17690948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-synuclein alters proteasome function, protein synthesis, and stationary phase viability.
    Chen Q; Thorpe J; Keller JN
    J Biol Chem; 2005 Aug; 280(34):30009-17. PubMed ID: 15941712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology.
    Ulusoy A; Febbraro F; Jensen PH; Kirik D; Romero-Ramos M
    Eur J Neurosci; 2010 Aug; 32(3):409-22. PubMed ID: 20704592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice.
    Diepenbroek M; Casadei N; Esmer H; Saido TC; Takano J; Kahle PJ; Nixon RA; Rao MV; Melki R; Pieri L; Helling S; Marcus K; Krueger R; Masliah E; Riess O; Nuber S
    Hum Mol Genet; 2014 Aug; 23(15):3975-89. PubMed ID: 24619358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy.
    Stefanova N; Kaufmann WA; Humpel C; Poewe W; Wenning GK
    Acta Neuropathol; 2012 Jul; 124(1):51-65. PubMed ID: 22491959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-Synuclein Decreases the Abundance of Proteasome Subunits and Alters Ubiquitin Conjugates in Yeast.
    Popova B; Galka D; Häffner N; Wang D; Schmitt K; Valerius O; Knop M; Braus GH
    Cells; 2021 Aug; 10(9):. PubMed ID: 34571878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations.
    Li W; West N; Colla E; Pletnikova O; Troncoso JC; Marsh L; Dawson TM; Jäkälä P; Hartmann T; Price DL; Lee MK
    Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2162-7. PubMed ID: 15684072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.